Eosinophil-related diseases during treatment with glucagon-like peptide one receptor (GLP-1 RA): a case report and review of the literature

Glucagon-like peptide one-receptor agonists (GLP-1 RA) are drugs that differ in their pharmacological composition and homology to human GLP-1 and are used most frequently for the treatment of type 2 diabetes and weight loss. There are isolated reports of eosinophilic adverse reactions associated wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Posso-Osorio, Iván, Vargas-Potes, Carlos Julio, Mejía, Mauricio, Cañas, Carlos A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Case Based Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10412476/
https://www.ncbi.nlm.nih.gov/pubmed/37199890
http://dx.doi.org/10.1007/s10067-023-06612-w
Descripción
Sumario:Glucagon-like peptide one-receptor agonists (GLP-1 RA) are drugs that differ in their pharmacological composition and homology to human GLP-1 and are used most frequently for the treatment of type 2 diabetes and weight loss. There are isolated reports of eosinophilic adverse reactions associated with GLP-1 RA. We present the case of a 42-year-old female patient who, after starting weekly subcutaneous semaglutide, developed eosinophilic fasciitis with favorable clinical evolution after the discontinuation of semaglutide and the initiation of immunosuppression. A review of the eosinophilic adverse events that have been previously reported with GLP-1 RA is provided.

Ejemplares similares